Antitrust

Introduction

This page contains references to documents related to the application of antitrust laws in the pharmaceutical sector. Although conflicts of interest are a primary focus, the range of documents extends beyond this main theme.

United States

FTC | DOJ | OIG | Statutes | Antitrust - Guidelines | Court decisions

FTC

FTC Studies

• "Generic Drug Entry Prior to Patent Expiration" (July 2002)
• Prepared Statement of the Federal Trade Commission On Barriers To Generic Entry, Presented by Commissioner Jon Leibowitz Before the Special Committee on Aging, United States Senate.

FTC reports and press releases

• Prepared statement, Protecting consumer access to generic drugs: the benefits of a legislative solution to anticompetitive settlements in the pharmaceutical industry (May 2, 2007)
• Testimony of Phillip A. Proger regarding "H.R. 1902, Protecting Consumer Access to Generic Drugs Act of 2007" (May 2, 2007)
• Press release, FTC Testifies Before U.S. Senate on Barriers to Entry of Generic Drugs (May 2, 2007)
• Press release, Federal Register Notice Issued on Authorized Generic Drug Study; FTC/DOJ File Joint Comments with NY State Assembly Committee on the Unauthorized Practice of Law (April 30, 2007)
• Comments received, Agency Is Considering Conducting a Study to Analyze the Use and Likely Short- and Long-run Competitive Effects of Authorized Generic Drugs in the Prescription Drug Marketplace
• Press release, FTC Staff Files Comments with New Jersey Assemblywoman on PBM Legislation; Commission Seeks Public Comments on Orders to Collect Information on Food Marketing (April 20, 2007) - Statement of April 17, 2007
• Press release, FTC Testifies on Alternative Hormone Replacement Therapy (April 19, 2007) - Text of testimony
• FTC & DOJ,  Antitrust enforcement and intellectual property rights: Promoting Innovation and Competition (April 2007)
• Press release, FTC Provides Senate Testimony on Anticompetitive Patent Settlements in the U.S. Pharmaceutical Industry  (January 17, 2007) - Prepared statement
• Press release, Bureau of Competition Issues FY 2006 Summary of Pharmaceutical Company Settlement Agreements (January 17, 2007)
• Agreements filed with the FTC under the Medicare Prescription Drug, Improvement and Modernization Act of 2003 - Summary of Agreements Filed in FY 2006
• Agreements filed with the FTC under the Medicare Prescription Drug, Improvement and Modernization Act of 2003 - Summary of Agreements Filed in FY 2005

FTC cases

• Commission to file amicus brief in In re Tamoxifen Citrate Antitrust Litigation (December 2, 2005)
• FTC amicus brief related to In re Tamoxifen Citrate Antitrust Litigation (November 30, 2005)
• FTC requests re-hearing in Schering-Plough case (April 22, 2005)
• FTC Amicus Brief in Teva v. Pfizer (February 2005)
• Commission response to FDA citizen petition filed by IVAX regarding ANDA for Zocor (April 7, 2005)
• FTC Amicus Brief in Andrx v. Kroger (July 2004)
• FTC Amicus Brief in Teva v. Pfizer (March 2004)
• Commission rules Schering-Plough, Upsher, and AHP illegally delayed entry of lower-cost generic drug (K-Dur 20) (December 18, 2003)
• FTC charges Bristol-Myers Squibb with pattern of abusing government processes to stifle generic competition (March 7, 2003)
• FTC Amicus Brief in SKB v. Apotex (March 2003)
• Consent order resolves charges that Biovail and Elan agreement unreasonably restrained competition in market for generic anti-hypertension drug (June 27, 2002)
• Wrongful 'Orange Book' listing raises red flag with FTC; Leads ton consent order with Biovail Corp. concerning its drug Tiazac (April 23, 2002)
• FTC agreement with American Home Products Corp. would protect consumers from anticompetitive practices (February 19, 2002) (payments by Schering-Plough to delay entry of generic K-Dur 20) 
• FTC Amicus Brief related to In re Buspirone Antitrust Litigation (January 2002)
• Consent agreement resolves complaint against pharmaceutical companies Hoechst Marion Roussel and Andry (April 2, 2001)
• FTC reaches record financial settlement to settle charges of price-fixing in generic drug market (Mylan, $100 million) (November 29, 2000)
• Bayer settles FTC charges (aspirin regimen therapy) (January 11, 2000)
• Mylan, nation's second largest generic drug maker, charged with restraint of trade, conspirarcy & monopolization (two anti-anxiety drugs, lorazepam and clorazepate) (December 21, 1998)
• Merck settles FTC charges that its acquisition of Medco could cause higher prices and reduced quality for prescription drugs (August 27, 1998)
• FTC gives final approval to Lilly order: pledges continued monitoring for anticompetitive practioces (July 31, 1995)

top chapter

DOJ cases

• Amicus Brief in FTC v. Schering-Plough (May 2006)
• U.S. announces $155 settlement of Medco False Claims Case (October 23, 2006) (bis)
• Serono to pay $704 million for the illegal marketing of AIDS drug (Serostim) (October 17, 2005)
• GlaxoSmithKline pays $150 million to settle drug pricing fraud case (September 20, 2005)
• Schering-Plough to pay $345 million to resolve criminal and civil liabilities for illegal marketing of Claritin (July 30, 2004)
• Warner-Lambert to pay $430 million to resolve criminal & civil health care liability relating to off-label promotion (Neurontin) (May 13, 2004)
• Rhône-Poulenc Biochimie, subsidiary of Aventis, agrees to plead guilty to fixing prices of a medical product ingredient (September 18, 2003)
• AstraZeneca pleads guilty to helathcare crime; company agrees to pay $355 million to settle charges (June 20, 2003) - See also FDA press release
• Pharmaceutical company, Dey, Inc. to pay US and Texas $18.5 million to settle allegations of Medicaid fraud (June 11, 2003)
• Drug giant Pfizer & two subsidiaries to pay $49 million for defrauding drug Medicaid rebate program (October 28, 2002)
• Tap Pharmaceutical Products Inc. and seven others charges with health care crimes; company agrees to pay $875 million to settle charges (October 3, 2001)
• Former medical company official sentenced to 10 months, charged with fraud against the United States (September 4, 2001)
• Bayer to pay $14 million to settle claims for causing providers to submit fraudulent claims to 45 state Medicaid programs (January 23, 2001)
• Bayer agrees to settle allegations that it caused providers to submit fraudulent claims to 47 state Medicaid programs (September 19, 2000)
• Two German firms and two U.S. corporations agree to plead guilty to participating in international vitamin cartels (May 5, 2000) (Merck KgaA, Degussa-Huls  AG, Nepera, Reilly) ($33 million)
• Abbott Laboratories to remedy deficiencies in medical diagnostic devices and pay $100 million (November 2, 1999)
• US pharmaceutical giant agrees to pay criminal fines for participating in two international food additives conspiracies (Pfizer to pay $20 million) (July 19, 1999)
• Novartis Pharmaceuticals to pay $8 million to settle allegations of overcharing veterans affairs (March 11, 1999)
• University of Minnesota pays $32 million to settle allegations of selling an unlicensed drug and mishandling NIH grant funds (November 17, 1998)
• Circa Pharmaceuticals pays US $2.7 million to resolve liability for untested generic drugs (March 28, 1996)

OIG

• CIA with Serono (2005)
• CIA addendum with SmithKline Beecham (2005)
• CIA with King
• CIA with Pfizer (2004)
• CIA with Schering-Plough (2004)
• CIA with Abbott (2003)
• CIA with Bayer (2003)
• CIA with AstraZeneca (2003)
• CIA with TAP (2001

Statutes

• Sherman Act, 15 U.S.C. § 1-15
• Clayton Act 15 U.S.C. §§ 12-27, 29 U.S.C. §§ 52-53
• Robinson-Patman Antidiscrimination Act

Antitrust - Guidelines

• Horizonal Merger Guidelines
• Antitrust Guidelines for the Licensing of Intellectual Property>
• Statements of Antitrust Enforcement Policy and Analytical Principles Relating to Health Care and Antitrust
• Antitrust Enforcement Guidelines for International Operations
• Antitrust Guidelines for Collaborations Among Competitors on the FTC web site

top chapter

Court Decisions

Supreme court

• Leegin Creative Leather Products Inc. v. PSKS Inc, (2007) (overruling Dr. Miles Medical Co. v. John D. Park & Sons Co., 220 U.S. 373 (1911)).
• Illinois Tool Works Inc. v. Independent Ink, Inc., 547 U.S. 28 (2006)
• State Oil Co. v. Khan, 522 U.S. 3  (1997) (overruling Albrecht v. Herald Co., 390 U.S. 145 (1968))
• Palmer v. BRG of Ga., Inc., 498 U.S. 46 (1990)
• Business Electronics Corp. v. Sharp Electronics Corp., 485 U.S. 717 (1988)
• Monsanto Co. v. Spray-Rite Service Corp., 465 U.S. 752 (1984)
• Arizona v. Maricopa County Medical Soc., 457 U.S. 332 (1982)
• Continental T. V., Inc. v. GTE Sylvania Inc., 433 U.S. 36 (1977) (overruling United States v. Arnold, Schwinn & Co., 388 U.S. 365 (1967))
• White Motor Co. v. United States, 372 U.S. 253 (1963)
• United States v. Colgate & Co., 250 U.S. 300 (1919)

Pharmaceutical cases

• Abbott v. Teva, 432 F. Supp. 2d 408 (D.C.Del. 2006)
• In re Abbott Lab. Norvir Antitrust Litigation, 442 F. Supp. 2d 800 (N.D.Cal. 2006)
• Andrx v. Biovail, 256 F.3d 799 (D.C.Cir. 2001) xxx
• Andrx v. Biovail, 175 F.Supp. 2d 1362 (S.D.Flo. 2001)
• Twin City Fund v. Astra Akietbolag, 207 F. Supp. 2d 221 (S.D.N.Y. 2002) (product: prilosec)
• Biovail v. Hoescht, 49 F. Supp. 2d 750 (D.N.J. 1999) xxx
• Xechem v. BMS, 372 F. 3d 899 (7th Cir. 2004)
• Vista v. BMS, 287 F. Supp. 2d 65 (listing of patents to extend Taxol's protection) (D.D.C. 2003)
• BMS v. Ben Venue Labs, 90 F. Supp. 2d 540 (D.N.J. 2000)
• In re Buspirone Patent Litigation, (S.D.N.Y. 2002) (agreement between BMS and Schein)
• In re Cardizem CD Antitrust Litigation, (6th Cir. 2004) (reverse payment in patent settlement agreement between Aventis and Andrx)
• In re CiprofloxacinHydrochloride Antitrust Litigation, (E.D.N.Y. 2005, 2003, 2001) xxx
• Eon Labs v. Watson, 164 F. Supp. 2d 350 (S.D.N.Y. 2001)
• Eli Lilly v. American Cyanamid, (S.D.Ind. 2001) (product: Ceclor)
• Eli Lilly v. Zenith (product: Ceclor), 172 F. Supp. 2d 1060 (S.D.Ind. 2001)
• Ryan-House v. GSK, (E.D.Va. 2005) (product: Augmentin)
• Nichols v. SmithKline, (E.D.Pa. 2005) (product: Paxil)
• In re K-Dur Antitrust Litigation, (D.N.J. 2004)
• In re Lorazepam Antitrust Litig., 205 F.R.D. 369 (D.D.C. 2002) (Mylan's attempt to control exclusively the sources of raw ingredients)
• In re Lupron Marketing and Sales Practices Litigation, (D.Mass. 2005) (marketing scheme)
• FTC v. Mylan, 99 F. Supp. 2d 1 (D.D.C. 1999) (product: lorazepam and clorazepate)
• Morton Grove v. Par, (N.D.Ill. 2006)
• In re Neurontin Antitrust Litigation, (N.J. 2002)
• In re Nifepidine (Adalat) Antitrust Litigation, (D.D.C. 2004)
• Organon v. Teva, 244 F. Supp. 2d 370 (D.N.J. 2002) (product: remeron)
• Organon v. Mylan, 293 F. Supp. 2d 453 (D.N.J. 2003) (product: remeron)
• In re Relafen Antitrust Litigation, (D.C.Mass. 2005) (patent listing by GSK)
• In re Remeron Antitrust Litigation, (D.N.J. 2005)
• Schering-Plough v. FTC, 402 F. 3d 1056 (patent settlement agreement) (11th Cir. 2005)
• SmithKline Beecham v. Apotex (E.D.Pa. 2004)
• In re Tamoxifen Citrate Antitrust Litigation, (reverse payment in patent settlement agreement) (2nd Cir. 2006)
• In re Terazosin Hydrochloride Antitrust Litigation, 352 F. Supp. 2d 1279 (S. D. Flo.) (2005)
• In re Terazosin Hydrochloride Antitrust Litigation / Valley Drug Co. v. Geneva Pharms, 344 F.3d 1294 (11th Cir. 2003)
• In re Terazosin Hydrochloride Antitrust Litigation, 164 F. Supp. 2d 1340 (S.D.Fla. 2000)
• In re Terazosin Hydrochloride Antitrust Litigation, (S.D. Fla. 2000)(patent settlement agreement between Abbott and Geneva)
• In re Warfarin Sodium Antitrust Litigation, (3d Cir. 2004)
• Warner Lambert v. Purepac, (N.J.D.C. 2000)
• In re Wellbutrin Zyban Antitrust Litigation, (E.D.Penn. 2006)
• J.B.D.L. Corp. v. Wyeth-Ayerst Lab. 485 F.3d 880 (2007)

See also

• For a list of settlements reached, see Cafferty and Faucher's article on Indirect Purchaser Class Action Settlements (June 2006)
• For a discussion of pharma antitrust cases, see G. G. Gordon, A Summary of Recent Pharmaceutical Cases Raising Intellectual Property Antitrust Issues (March 2005)

top of the page

European Union

European Commission | Statutes | Guidelines | Court decisions

Treaty, Directives and regulations

• Article 81 of the EC Treaty
• Article 82 of the EC Treaty
• Council Regulation (EC) No 1/2003 of 16 December 2002 on the implementation of the rules on competition laid down in Articles 81 and 82 of the Treaty
• Commission Regulation (EC) No 2790/1999 of 22 December 1999 on the application of Article 81(3) of the Treaty to categories of vertical agreements and concerted practicesText with EEA relevance - Official Journal L 336, 29.12.1999, pages 21-25
• Commission Regulation (EC) No 772/2004 of 27 April 2004 on the application of Article 81(3) of the Treaty to categories of technology transfer agreements  - Official Journal L 123, 27.04.2004, pages 11-17

European Commission

Guidelines

• Commission notice - Guidelines on Vertical Restraints - Official Journal C 291, 13.10.2000, pages 1-44
• Commission Notice - Guidelines on the applicability of Article 81 to horizontal co-operation agreements - Official Journal C 3 of 06.01.2001, p. 2.
• Commission Notice - Guidelines on the application of Article 81 of the EC Treaty to technology transfer agreements - Official Journal C 101, 27.04.2004, pages 2-42
• Communication from the Commission - Notice - Guidelines on the application of Article 81(3) of the Treaty - Official Journal C 101, 27.04.2004, pages 97-118
• Modernisation of EC antitrust enforcement rules. Council Regulation (EC) No 1/2003 and the modernisation package
• The Competition rules for supply and distribution agreements
• Notice on exclusive dealing contracts with commercial agents, OJ 139, 24.12.1962, p. 2921/62
• Notice on the definition of the relevant market for the purposes of Community competition law, OJ C 372 on 9/12/1997)
• Commission Notice on the handling of complaints by the Commission under Articles 81 and 82 of the EC Treaty - Official Journal C 101, 27.04.2004, pages 65-77
• Commission Notice on informal guidance relating to novel questions concerning Articles 81 and 82 of the EC Treaty that arise in individual cases (guidance letters) - Official Journal C 101, 27.04.2004, pages 78-80
• Commission Notice - Guidelines on the effect on trade concept contained in Articles 81 and 82 of the Treaty - Official Journal C 101, 27.04.2004, pages 81-96
• Commission Notice on agreements of minor importance which do not appreciably restrict competition under Article 81(1) of the Treaty establishing the European Community (de minimis)  Official Journal C 368, 22.12.2001, pages 13-15
• Commission Notice on the rules for access to the Commission file in cases pursuant to Articles 81 and 82 of the EC Treaty, Articles 53, 54 and 57 of the EEA Agreement and Council Regulation (EC) No 139/2004
• Guidelines on the method of setting fines (2006)
• Commission Notice on the non-imposition or reduction of fines, published in OJ C 45 19.02.2002

Cases

• AstraZeneca decision of 15 June 2005 (COMP/A. 37.507/F3 )
• GSK Pricing System - Decision of the European Commission (8 May 2001) - Cases: IV/36.957/F3 Glaxo Wellcome, IV/36.997/F3 Aseprofar and Fedifar , IV/37.121/F3 Spain Pharma , IV/37.138/F3 BAI , IV/37.380/F3 (C (2001) 1202) - OJ L 302, 17.11.2001, p.1-43
• Vitamin case - Decision of the European Commission - Prohibition with fines decision, (21 November 2001), (Case COMP/E-1/37.512), OJ L 6, 10.01.2003, p.1-89 - F. Hoffmann-La Roche AG, BASF AG, Aventis SA (formerly Rhône-Poulenc), Lonza AG, Solvay Pharmaceuticals BV, Merck KgaA , Daiichi Pharmaceutical Co. Ltd,, Eisai Co. Ltd, Kongo Chemical Co. Ltd, Sumitomo Chemical Co. Ltd
• Choline Chloride - Decision of the European Commission - (9 December 2004) (Case COMP / E-2 / 37.533 ) - Akzo Nobel, BASF A.G. Bioproducts Inc. Chinook, DuCoa, UCB
• Citric Acid Case - Decision of the European Commission - (5 December 2001) (Case No COMP/E-1/36 604) - OJ L 239, 06.09.2002, p.18-65 - Archer Daniels Midland Company Inc., Cerestar Bioproducts BV, F. Hoffmann-La Roche AG, Haarmann & Reimer Corporation, Jungbunzlauer AG
• Sodium Gluconate Case - Akzo Nobel NV - COMP/36.756
• MCAA (Monochloroacetic acid) Case - Akzo Nobel AB - COMP/37.773
• Methionine / PO Case - Degussa-Hüls AG - COMP/37.519
• IMS Case - COMP/37.055  - COMP/38.044 - COMP/36.816
• Astra AB - COMP/37.507  Generics/Astra Zeneca
• PO/Methylglucamine Case - Aventis Pharma AG - COMP/37.978
• Sandoz  Invoice Case - 87/409/EEC: Decision of the European Commission (13 July 1987)(IV/31.741)  OJ L 222, 10.8.1987, p. 28–34
• BASF - COMP/37.779  BASF+Sonatrach+3
• Bayer - COMP/37.769  Bayer+Lyondell+1
• Bayer - COMP/38.443  Rubber chemicals
• Bayer - COMP/38.176  DuBay GmbH + DuPont Deutschland Holding GmbH and Co. KG + Bayer AG
• Chiron - COMP/38.153  Chiron Corporation + F. Hoffmann-La Roche Ltd
• Degussa AG - COMP/37.359  Degussa+Norddeutsche Affinerie - Hydrogen peroxide (and perborate) - COMP/38.645Methacrylates
• Degussa UK - COMP/37.857  PO/Organic peroxyde
• Eisai - COMP/36.932  Eisai+Pfizer
• Eka Chemicals - COMP/37.773  MCAA (Monochloroacetic acid) -
• Hoechst AG - COMP/37.370  Sorbates - COMP/37.773  MCAA (Monochloroacetic acid)
• Hoffman - COMP/38.359  PO / Electrical and mechanical carbon and graphite products
• Hoffmann-La Roche F - COMP/38.153  Chiron Corporation + F. Hoffmann-La Roche Ltd

Pfizer Inc

• COMP/36.932  Eisai+Pfizer
• COMP/37.671  PO/Food flavour enhancers
• COMP/37.590  Pfizer+HMR+Inhale+1

Solvay NV

• COMP/36.732  Solvay+Sisecam+6
• COMP/39.004  ex-33133C/CARBONATE DE SOUDE-SOLVAY
• COMP/37.650  Solvay + Elf Atochem + Viniclor
• COMP/39.003  ex-33133B/CARBONATE DE SOUDE-SOLVAY-CFK
• COMP/37.841  Elf Atochem+Solvay+

Solvay Sodi Holding

• COMP/36.732  Solvay+Sisecam+6

Solvay-Sodi SPJSCO

• COMP/36.732  Solvay+Sisecam+6

Sonatrach

• COMP/37.779  BASF+Sonatrach+3
• COMP/37.779  BASF+Sonatrach+3

• Bayer Corporation - COMP/37.769  Bayer+Lyondell+1

Reports

• COMP/37.773 MCAA
• Report on Competition Policy 2005
• DG Competition discussion paper on the application of Article 82 of the Treaty to exclusionary abuses Public consultation
• Report on Competition Policy 2004
• Report on Competition Policy 2003

top chapter

Court decisions (list)

Articles 81 EC

• Case T-26/02 - Daiichi Pharmaceutical v. Commission (15 March 2006) (level of fine)
• Case T-15/02 - BASF v. Commission (15 March 2006) (level of fine)
• Case C-277/87 - Judgment of the Court of 11 January 1990. - Sandoz prodotti farmaceutici SpA v Commission of the European Communities -  (Concept of agreement)

Articles 82 EC

• Case C-418/01- Judgment of the Court of 29 April 2004 - IMS Health - (Copyright – Refusal to grant a licence)
• Case C-53/03, Syfait

Parallel imports

• C-223/01 AstraZeneca (Losec Entero / Omeprazol)
• C-15/01 Paranova (Losec)
• C-443/00   Aventis
• C-172/00 Ferring (Minirin Spray)
• C-143/00 Boehringer(exhaustion of the rights conferred by the trade mark)
• T-123/00 Thomae
• C-443/99   Merck, Sharp & Dohme v. Paranova (Exhaustion of the rights conferred by the trade mark) (Proscar)
• C-94/98 Rhône-Poulenc (Parallel imports) (Zimovane)
• C-379/97  Pharmacia & Upjohn (Trade-mark rights) (clindamycin)
• C-267/95 & C-268/95 - Merck v. Primecrown (Parallel imports of unpatentable pharmaceuticals)(Innovace)
• C-201/94  Smith & Nephew (Ditropan)
• C-232/94   Rhône-Poulenc (Repackaging of trade-marked products)(Orudis)
• C-436/93  (C-427/93, C-429/93 and C-436/93) BMS v. Paranova (Repackaging of trade-marked products)
• C-51/93   Meyhui (language of description)
• C-191/90  Generics (Compulsory licences) (Cimetidine)
• C-10/89  HAG (trademark) (coffee)
• C-249/88 Commission v. Belgium (National legislation on the price of pharmaceutical products) 
• C-434/85 Generics (Compulsory licence under a patent)
• C-87/85 & 88/85 Cophalux (Rules governing the importation and marketing of medicinal products)
• C-238/82  Duphar (restrictions on access to certain medicinal preparations)
• C-181/82  Roussel (Regulation of prices for imported medicines)
• C-247/81 Commission v. Germany (Conditions for placing on the market)
• C-1/81    Pfizer v. Eurim-Pharm (trade mark)
• C-187/80  Merck v. Stephar (patent)(Moduretic)
• C-102/77 Hoffmann-La Roche (Re-packaging of trade-marked goods)
• C-104/75 De Pejper
• C-16/74  Centrafarm v. Winthrop (trade mark)
• C-15/74  Centrafarm v. Sterling (parallel patents)

Trade Associations

• EFPIA, Comments on the Commission's Green Paper on damages actions for breach of the EC antitrust rules (April 2006)
• EFPIA, DG Competition Discussion Paper on the Application of Article 82 EC Treaty to Exclusionary Abuses Public Consultation - EFPIA's Observations (March 2006)
• EFPIA, Competition policy in the pharmaceutical sector - Article 82 EC: Can It Be Applied to Control Sales By Pharmaceutical Manufacturers to Wholesalers? (November 2004)

top chapter

National cases

• BMJ, News, Clare Dyer, Drug company fined [Napp] £2.2m for abusing its dominant position, 324 p.188 (2002)
• France, Décision 05-D 72 du 20 décembre 2005 relative à des pratiques mises en œuvre par divers laboratoires dans le secteur des exportations parallèles de médicaments
• France, arrêt de la Cour de Cassation n° 1040 du 14 décembre 2004, PharmaLab v. GSK
• France, Arrêt de la cour d’appel de Paris (1re chambre, section H) en date du 16 juillet 2002 relatif au recours formé par la SA Pharmajet contre la décision 2002-MC-09 (*) du Conseil de la concurrence en date du 12 juin 2002 relative à une saisine présentée par la société Pharmajet
• Arrêt de la cour d'appel de Paris du 26 juin 2002 dans l'affaire 02-MC-07, PharmaLab
• France, Décision 02-MC-07 du 15 mai 2002 relative à une saisine présentée par la société Pharma-Lab

top of the page

Switzerland

Comco | | Price Supervisor | Statutes | Court decisions

Comco

• DPC 2007/1, récapitulatif de procédures liées aux coûts de la santé, p.20 et 21
• Communiqué de presse, La Comco ouvre une enquête sur les prix recommandés de trois médicaments «hors-liste» (27 juin 2006)
• DPC 2006/3, prix du médicament Thalidomid,
• DPC 2006/3, procédure Galenica-Unione, p.498,
• DPC 2006/3, IMS Health p.510,
• DPC 2006/3, contrats tarifaires dans les assurances complémentaires, p.513
• DPC 2006/1, Documed, p.14
• DPC 2005/4, procédure Galenica-Uni-Chem, p.638
• Communiqué de presse, La Comco ouvre une enquête portant sur la publication d'informations sur les médicaments (1 juillet 2005)
• DPC 2005/1, distribution de médicaments vétérinaires, p.14
• DPC 2004/4, distribution de médicaments vétérinaires, p.1040
• Communiqué de presse, Enquête de la Commission de la concurrence dans le domaine de la distribution de produits vétérinaires: l'industrie modifie sa pratique (28 octobre 2004)
• Communiqué de presse, La Comco classe l'enquête dans le secteur de la médecine complémentaire  (6 mai 2004)
• DPC 2004/3, fusion Sanofi-Synthélabo et Aventis, p.812
• Communiqué de presse, La législation sur les produits thérapeutiques ne permet pas à l'industrie pharmaceutique de s'entendre sur les prix et les rabais accordés aux hôpitaux publics (23 septembre 2003)
• Décision du 19 avril 2000 concernant l’enquête selon l’article 27 LCart sur le cas des accords sur les prix/répartition des ventes sur le marché des vitamines relatif à des accords illicites selon l’article 5 LCart (DPC 2000/2, p.186)
• DPC 2002/1, résumé du cas Sanphar, p.189
• DPC 2001/1, rémunération des pharmaciens et autres questions du marché de la santé, p.28
• Communiqué de presse, La Comco recommande le remboursement du prix payé lors de l'achat de produits médicaux à l'étranger  (21 décembre 2000)
• Communiqué de presse, Ouverture d'une enquête concernant la distribution de médicaments (28 avril 2000)
• DPC 1999/2, commentaires sur le projet de loi sur les produits thérapeutiques, p.281
• DPC 1999/1, politique de la santé, p.28
• DPC 1998/1, procédure Roche-Corange, p.62 et Merck, p.96
• Communiqué de presse, La Commission de la concurrence approuve la vente de médicaments par correspondance  (9 décembre 1998)

Price Supervisor

• Stellungnahme des Preisüberwachers zum Tarifvertrag zwischen dem Schweizerischen Apothekerverband und santésuisse (LOA III) (11 décembre 2006)
• Durchschnittswerte sind Glücksache (8 septembre 2006)
• Newsletter, Medikamenten-Preissenkungsrunde: Zwischenbilanz nach einem Jahr  (5 septembre 2006)
• Preissenkungsaktion BAG per 1.9.2006 – Zwischenbilanz (1er septembre 2006)
• Newsletter, Preissenkungen bei Medikamenten  (juillet 2006)
• Newsletter,  Leistungsorientiertes Abgeltungssystem für Apotheker (LoA II) (juin 2006)
• Newsletter, Preisüberwacher beantragt vereinfachte und preisgünstigere Zulassungspraxis für Spitalmedikamente (mai 2006)
• Wettbewerbsmängel bei der Preisgestaltung der Medikamente in der Schweiz (26 juillet 2006)
• Prix administrés et médicaments: Propositions de mesures sur les prix dans le domaine des médicaments pris en charge par les assurances-maladie (liste des spécialités - LS) - 20 propositions de la Surveillance des prix (25 juillet 2006) - Etude (en allemand)
• Newsletter,  Medikamentenpreise senken – aber wie?  (juin 2005)
• Explosion des coûts des médicaments: pas un problème de quantités (27 novembre 2003) - Documentation pour la presse

Statutes

• Loi fédérale du 6 octobre 1995 sur les cartels et autres restrictions à la concurrence (Loi sur les cartels, LCart)
• Ordonnance du 12 mars 2004 sur les sanctions en cas de restrictions illicites à la concurrence (OS LCart)

Comco Guidelines

• Communication PME
• L'appréciation des accords verticaux
• Procédure de consultation sur l'appréciation des accords verticaux (Révision)
• Les conditions d’admissibilité, conformément à la Loi sur les cartels, d’accords sur l’utilisation de schémas de calcul
• Notes explicatives relatives à l'ordonnance sur les sanctions LCart (OS LCart)
• Notice sur le déroulement des perquisitions

Court decisions

• ATF 125 I 474 (MediServices), aussi dans DPC 2000/1, p.107
• 2A.387/2000 (Rhone-Poulenc + Merck) (24 avril 2001)

Divers

• Examens de l'OCDE de la réforme de la règlementation, Suisse, Saisir les opportunités de croissance, passage sur l’indépendance économique et politique des membres de la Commission de la concurrence, p.133 (2006)